GT Biopharma (GTBP) Assets Average (2011 - 2026)
GT Biopharma (GTBP) posted quarterly Assets Average of $9.1 million for Q1 2026, up 162.73% year-over-year from $3.4 million in Q1 2025, and up 45.67% quarter-over-quarter from $6.2 million in Q4 2025.
GT Biopharma (GTBP) Assets Average (2011 - 2026) Analysis & Trends
GT Biopharma (GTBP) has reported Assets Average for 15 consecutive years, with $9.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average rose 162.73% year-over-year to $9.1 million; the TTM figure through Mar 2026 stood at $9.1 million (up 162.73% YoY), while the FY2025 annual figure was $6.2 million, down 32.73% from the prior year.
- Assets Average rose to $9.1 million in Q1 2026 per GTBP's latest filing, from $6.2 million in the prior quarter.
- Across five years, Assets Average topped out at $29.8 million in Q1 2022 and bottomed at $3.4 million in Q1 2025.
- Historically, Assets Average has averaged $14.3 million across 5 years, with a median of $15.1 million in 2023.
- Annual changes were most pronounced in 2025 — Assets Average plunged 71.32% — and 2026, when it surged 162.73%.
- GT Biopharma's Assets Average stood at $18.9 million in 2022, then decreased by 19.97% to $15.1 million in 2023, then slumped by 63.67% to $5.5 million in 2024, then climbed by 13.07% to $6.2 million in 2025, then jumped by 45.67% to $9.1 million in 2026.
- Business Quant data shows GTBP's Assets Average at $9.1 million in Q1 2026, $6.2 million in Q4 2025, and $5.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | GT Biopharma | 8.38 Mn | 8.38 Mn | - | 9.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.05 Mn |
| Dec 31, 2025 | 6.21 Mn |
| Sep 30, 2025 | 5.72 Mn |
| Jun 30, 2025 | 4.89 Mn |
| Mar 31, 2025 | 3.45 Mn |
| Dec 31, 2024 | 5.50 Mn |
| Mar 31, 2024 | 12.01 Mn |
| Dec 31, 2023 | 15.13 Mn |
| Sep 30, 2023 | 17.15 Mn |
| Jun 30, 2023 | 19.12 Mn |
| Mar 31, 2023 | 18.41 Mn |
| Dec 31, 2022 | 18.90 Mn |
| Sep 30, 2022 | 22.62 Mn |
| Jun 30, 2022 | 25.80 Mn |
| Mar 31, 2022 | 29.80 Mn |
| Dec 31, 2021 | 33.98 Mn |
| Sep 30, 2021 | 37.68 Mn |
| Jun 30, 2021 | 33.61 Mn |
| Mar 31, 2021 | 16.65 Mn |
| Dec 31, 2020 | 3.29 Mn |